23 Breast Cancer Clinical Trials in La Jolla, CA (2026)

Q: How do I join a clinical trial in La Jolla?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you.

Recruiting Breast Cancer Studies in La Jolla

NCT05952557Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high ...

La Jolla, CAPHASE35,500 participantsAstraZeneca

View Study Details

NCT01042379Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learn...

La Jolla, CAPHASE25,000 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT06393374Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...

La Jolla, CAPHASE31,530 participantsMerck Sharp & Dohme LLC

View Study Details

NCT00477100Recruiting

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing sampl...

La Jolla, CA1,200 participantsM.D. Anderson Cancer Center

View Study Details

NCT06312176Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone rece...

La Jolla, CAPHASE31,200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03424005Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be perform...

La Jolla, CAPHASE11,132 participantsHoffmann-La Roche

View Study Details

NCT07085767Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for...

La Jolla, CAPHASE31,000 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT05232916Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk f...

La Jolla, CAPHASE3750 participantsGreenwich LifeSciences, Inc.

View Study Details

NCT07173751Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blind...

La Jolla, CAPHASE3558 participantsBioNTech SE

View Study Details

NCT06016738Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whos...

La Jolla, CAPHASE3510 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06790693Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole i...

La Jolla, CAPHASE3450 participantsHoffmann-La Roche

View Study Details

NCT06253871Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that...

La Jolla, CAPHASE1383 participantsIambic Therapeutics, Inc

View Study Details

NCT07029399Recruiting

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tum...

La Jolla, CAPHASE1361 participantsNiKang Therapeutics, Inc.

View Study Details

NCT07100106Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participa...

La Jolla, CAPHASE1285 participantsGenentech, Inc.

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

La Jolla, CAPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

NCT07007559Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in partic...

La Jolla, CAPHASE2120 participantsALX Oncology Inc.

View Study Details

NCT07227233Recruiting

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

The goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK...

La Jolla, CAPHASE2105 participantsUniversity of California, San Diego

View Study Details

NCT06763328Recruiting

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

This phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with st...

La Jolla, CAPHASE380 participantsCity of Hope Medical Center

View Study Details

NCT06126276Recruiting

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbocicli...

La Jolla, CAPHASE270 participantsNational Cancer Institute (NCI)

View Study Details

NCT05304962Recruiting

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR...

La Jolla, CAPHASE164 participantsRegor Pharmaceuticals Inc.

View Study Details

NCT07087691Recruiting

Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance

The goal of this research is to study a localization device for breast cancer called OneMark. This device will be studied in breast cancer surgery and during surveillance in patients being monitored f...

La Jolla, CANA60 participantsUniversity of California, San Diego

View Study Details

NCT06908928Recruiting

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-...

La Jolla, CAPHASE152 participantsMabwell (Shanghai) Bioscience Co., Ltd.

View Study Details

NCT06610097Recruiting

TNBC Gut Microbiota During Neoadjuvant Treatment

The gut microbiome is made up of the microbes (such as bacteria, viruses, and other organisms too small to see with the naked eye) that live in the digestive tract and has been shown to be important i...

La Jolla, CANA30 participantsScripps Health

View Study Details

About Breast Cancer Clinical Trials in La Jolla

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 23 breast cancer clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 20,680 participants. Research is being sponsored by AstraZeneca, QuantumLeap Healthcare Collaborative, Merck Sharp & Dohme LLC and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in La Jolla — FAQ

Are there breast cancer clinical trials in La Jolla?

Yes, there are 23 breast cancer clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 23 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 18, 2026 from ClinicalTrials.gov